Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next deadline: Oct 1, 2021 (Letter of inquiry)

Later deadlines: Nov 1, 2021 (Full proposal), Dec 7, 2021 (Letter of inquiry), Jan 7, 2022 (Full proposal)

Grant amount: Up to US $275,000

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: 

• Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review. Letters of intent are due by the "Letter of inquiry" dates listed above.
• Applications are due by 5:00 p.m. submitter's local time at the "Full proposal" dates listed above.

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.